Chad and I discussed the options with respect to how we would treat his valve – I ran through the three potential ways to manage it. One would be a mechanical valve with aggressive anticoagulation – blood thinner. The other would be a standard tissue valve with an expected longevity that would be relatively short since Chad is a young person. Finally, we had begun at that point the FDA study for the CorMatrix Extracellular Matrix tricuspid valve. That, of course, was an outgrowth of the work we’d already done. I was very familiar with the implantation, and we had the devices on hand ready to start the study. Chad wanted to participate in the study.